Duke-Harvard-MIT Anticancer Drug Development Fundamentals Workshop

for patient advocates

The Duke-Harvard-MIT Anticancer Drug Development Fundamentals Workshop will focus on how advocates can work more effectively with all stakeholders in the research process – industry, academia, government and technology – to ensure that the patient voice is incorporated across all conversations and decision making. The mission of the course is to introduce patient advocates to the U.S. Food and Drug Administration’s drug development and approval process. It is our belief that this training course will be important to cancer patients and has the potential to impact their treatment. We feel that patient advocates are essential in this conversation and are proud to help bring the patient perspective to these important discussions. The inclusion of patients, caregivers and advocates as equal stakeholders will add urgency to the conversations. Educating advocates on the various methods involved in drug development helps them understand the process and be better prepared to participate in projects that help accelerate cancer drug treatments.

Scholarships covering one night’s accommodation at the Le Méridien Cambridge-MIT Hotel will be provided to patient advocates traveling from outside the Boston area. Contact mary.ruemker@duke.edu for more information. .

No charge to attend for patient advocates. Advocates must be affiliated with a national or regional advocacy organization, or be involved in the conduct, oversight or development of oncology clinical trials.